Suchergebnisse - David Gruben

Characterization of Second‐Line Therapy After First JAK Inhibitor Use: Results From the CorEvitas Rheumatoid Arthritis Registry von Joshua F. Baker, Kristi V. Mizelle, Wassim Saikali, Page C. Moore, Hyung‐Joo Kang, David Gruben, Ahmed Shelbaya, Lori Stockert, Jacqueline O'Brien

Volltext

Real‐World Data of Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Taiwanese Patients With Rheumatoid Arthritis From a Drug‐Based Cohort Study von Song‐Chou Hsieh, Wei‐Sheng Chen, Jui‐Chieh Hu, Wan‐Yu Sung, Wen‐Chan Tsai, Hsiang‐Cheng Chen, Chung‐Ming Huang, Edward Kuo, David Gruben, Yi‐Hsing Chen

Volltext

Tofacitinib for the Treatment of Juvenile Idiopathic Arthritis: Patient‐Reported Outcomes in a Phase 3, Randomized, Double‐Blind, Placebo‐Controlled Withdrawal Trial von Hermine I. Brunner, Ekaterina Alexeeva, Marcia Bandeira, Ruy Carrasco, Jeffrey Chaitow, Peter Chiraseveenuprapund, Tracy V. Ting, Muferet Erguven, Beth Gottlieb, Sheila Knupp Oliveira, Pooja N. Patel, Seza Ozen, Claudia Saad Magalhaes, Inmaculada Calvo Penadés, David Gruben, Rebecca Germino, Holly B. Posner, Lori Stockert, Alberto Martini, Daniel J. Lovell, Nicolino Ruperto

Volltext